Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NK-92/5.28.z |
Synonyms | |
Therapy Description |
NK-92/5.28.z are NK-92 natural killer cell line-derived cells engineered to express a chimeric antigen receptor (CAR) that targets ERBB2 (HER2) and contains CD28 and the signaling domain from CD3zeta, which potentially results in tumor cell cytotoxicity and inhibition of tumor growth (PMID: 28879551, PMID: 25373520). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NK-92/5.28.z | HER2.taNK|Anti-HER2-CAR-CD28zeta NK-92 Cells | NK-92/5.28.z are NK-92 natural killer cell line-derived cells engineered to express a chimeric antigen receptor (CAR) that targets ERBB2 (HER2) and contains CD28 and the signaling domain from CD3zeta, which potentially results in tumor cell cytotoxicity and inhibition of tumor growth (PMID: 28879551, PMID: 25373520). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|